Abstract
Background
At present, one of the leading causes of death in the U.S. is believed to be adverse drug reactions. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] More than 20 million patients have taken at least 1 of the 5 drugs withdrawn from the market between September 1997 and September 1998. Seven drugs that were approved in 1993 and were withdrawn shortly later have contributed to 1002 deaths. 14 A study in 2002, showed that out of the 548 drugs that were approved in the U.S. between 1975-1999, fifty six (10.2 %) of them required a new black box warning or were withdrawn. 12 Thus, it is very important that the consumer as well as the practitioner become aware of dangerous drugs.
In 1979 the United Nations General Assembly first brought up the question of establishing a list of banned pharmaceutical products that could be exchanged between nations. Under resolution 37/137 (Annex I) of December 17 1982, the General Assembly requested the Secretary-General to organize the Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely restricted or Not Approved by Governments. The List is a continuing effort by the United Nations to circulate information on products that are harmful to health and the environment. 2 The first issue of the List covered less than 500 products regulated by 60 governments. The fifth issue which covered both pharmaceuticals and chemicals, included over 700 products regulated by 94 governments. By the eleventh and twelfth editions, the List had grown to include more than 1100 products regulated by 115 states. 2 At present the most Only 67 % of the 151 drugs that were on the List were banned by the U.S, while internationally 79 % were banned. This shows clearly that the U.S is not in complete agreement with the other countries on which drugs should be banned. There are many reasons why the policies of the U.S may differ from the international world. One reason might be a monetary benefit that drug companies/ government get from keeping a drug on the market. An example of a drug that has continued to be kept on the market is the anti-diabetic drug, rosiglitazone (Avandia). A drug might also be kept on the market in one country because it has a legitimate medical use, while in another country it may not be used medically and therefore is banned. For example, flunitrazepam, commonly known as the date rape drug "roofies", is used for the treatment of insomnia in many European countries. However, the FDA has not approved the use of flunitrazepam and it has deemed it an illegal substance.
2 Figure 1 also shows that only 19% of drugs were banned worldwide. This shows the lack of agreement on which drugs should be banned globally. It seems as if drugs that were banned worldwide had to have severe fatal adverse effects before they reached the eyes of the entire world. Drugs such as Fen-Fen which contained fenfluramine and phentermine were mainly removed after 20 years in the U.S. market due to a lawsuit which totaled over $13 billion in legal damages and of course potential fatal pulmonary hypertension and heart valve problems. 10 Both fenfluramine and its d-enantiomer, dexafluramine (Redux) were withdrawn in September 1997 worldwide. The second drug that made up Fen-fen, phentermin was banned in Sweden and the United Kingdom in 1981 and 2000 respectively. However, it is still marketed widely in the U.S. Another drug that is widely used in the U.S., but is banned internationally is the muscle relaxant, carisoprodol (Soma). In November 2007, the European Medicines Agency (EMA) recommended the suspension of marketing authorization after evidence of abuse and addiction from taking carisoprodol for back pain. Both Norway and Sweden have pulled carisoprodol off the market due to problems of dependence and intolerable side effects. As of 2008, the UK had planned to pull carisoprodol off the market due to increased risk of abuse, addiction, intoxication, and psychomotor impairment. 1 As of March 26 2010, the abuse potential of carisoprodol was brought to light in the U.S, as the DEA issued a Notice of hearing discussing the plan to place carisoprodol as a controlled substance. However, as of today carisoprodol is not a controlled substance under federal regulations while certain states consider it to be a controlled substance. These states include Alabama, Arizona, Arkansas, Florida, Georgia, Hawaii, Indiana, Kentucky, Louisiana, Massachusetts, Minnesota, Mississippi, New Mexico, Nevada, Oklahoma, Oregon and Texas. 4 While it is not a controlled substance in many states carisoprodol is only approved for short term use and prescribers are encouraged not to prescribe the drug to people with a background of addiction. It is interesting to notice that cariosprodol's metabolite, meprobamate which has significant anxiolytic properties was banned in Sweden in 1981 due to potential for abuse and addiction. 2 The UK was also planning to remove meprobamate due to severe side effects. 1 In the U.S. it has been classified as C-IV and was the best-selling tranquilizer for a long time before being replaced by the benzodiazepines.
A very controversial drug that has caused 13,000 lawsuits, while bringing in annual sales peaking at approximately $2.5 billion for GlaxoSmithKline in 2006, was the antidiabetic drug, rosiglitazone (Avandia). Rosiglitazone has been associated with increased risk of heart failure by 64 % over a seven year period. 7 In September 2010, the EMA suspended the drug from the European market completely. 5 The U.S. however, continues to market the drug with a black boxed warning.
Only 9% percent of drugs banned by the U.S. are available internationally as shown in Figure 2 . In November 2000, the FDA issued a public health advisory against the use of phenylpropanolamine, a psychoactive drug used as a stimulant, decongestant, and anorectic. Due to increased risk of strokes in young women, FDA requested the suspension of marketing of this drug and removed phenylpropanolamine from all OTC formulations in 2005. 11 While Canada has also withdrawn the drug, Europe continues to market it as a prescription and OTC drug. In the UK, it is sold in combinations with acetaminophen and caffeine as a cough and cold medication.
Another drug that has been banned in the U.S. but is available outside the U.S is pergolide (Permax), a dopamine receptor agonist used for the treatment of Parkinson's disease. Permax was approved in 1988 as an adjunctive therapy with levodopa in Parkinson's disease. Valvular heart disease was first described in association with pergolide in 2002. In 2003, the FDA asked Lilly to add valvulopathy (abnormality of cardiac valves) to the warnings section of Permax labeling. In 2006, the warning was upgraded to a black box warning, the FDA's strongest form of warning, because of new data concerning risks of heart valve damage. In 2007, it was removed from the U.S market due to increased rates of vavular dysfunction that were associated with using the drug. Pergolide is still used in other countries such as the UK and Australia for the treatment of Parkinson's disease, hyperprolactinemia and restless leg syndrome. 
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4 before they were also banned by the rest of the world. For the remaining 43%, differences were not detected. This shows that the U.S. may no longer be leader in observing, reporting and removing dangerous drugs from the market. This might be because the drug might have been introduced first internationally before it became available in the U.S. Thus, the time for the FDA to see any adverse effects from the drug might have lagged in comparison to other countries. For example, troglitazone, a thiazolidinediones used to treat diabetes was first introduced by a Japanese company. Due to an idiosyncratic reaction leading to hepatitis it was only approved in January 1997 in the U.S. However, it was already on the world market years before and was voluntarily removed in December 1997 in the UK and Japan due to concerns of hepatotoxicity. 2 Since the U.S. was late to approve the drug, logically they were only able to withdraw the drug by 2000.
Another drug that the U.S. was slow in removing from the market was the well known prescribed pain killer, dextropropoxyphene also called as propoxyphene (Darvon-N). This drug was usually combined with acetaminophen under the brand, Darvocet. Dextropropoxyphene which has been on the marker for more than 25 years came under fire in 1978 by consumer groups who claimed it caused suicides in many of the patient. The manufacturing company, Eli Lilly minimized the news and persuaded doctors that dextropropoxyphene was safe as long it was not mixed with alcohol. In 2004, products containing only dextropropoxyphene were removed in U.K. and later in June 2009, the EMEA recommend gradual withdrawal of all products containing dextropropoxyphene from the European Union. 6 A month later in the U.S., the FDA still decided to continue marketing dextropropoxyphene with a black box warning for the risk of overdose. On November 19 2010, the FDA finally pulled all forms of dextropropoxyphene from the market due to risk of heart arrhythmias. It is alarming that a drug such as dextropropoxyphene that had a high potential risk of causing heart problems was on the market for more than 20 years before it was completely removed. It is estimated that over 10 million people may have used these products. 
Conclusion
Drug withdrawal is an important task that involves continued surveillance and pharmacovigilance and is as important as the process of drug discovery and production. Since the establishment of the List, the dissemination of information on which drugs are banned has become easier. Nevertheless, countries tend to have different policies on which drugs to withdraw and when to withdraw them. The U.S. is on its own time course compared to other countries such as UK, Japan, Australia and Sweden and withdraws drugs based on the FDA's decisions. Likewise in order for a drug to be withdrawn globally, the side effects usually have to be severe enough to catch the attention of the entire world. In addition most of the time, drugs are kept on the market for many years before they are found to be more harmful than good. While there might be monetary benefits for each country in keeping these drugs on the market, the U.N. must step up the visibility of the withdrawal of dangerous drugs list. 
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